Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer.
AuthorsBronchud, Miguel H
Margison, Jennifer M
Lind, Michael J
Lucas, S B
Wilkinson, Peter M
AffiliationDepartment of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, England.
MetadataShow full item record
AbstractRecombinant human granulocyte colony-stimulating factor (G-CSF) has been shown to reduce neutropenia following cytotoxic therapy, thereby enabling dose escalation to improve the response rate. It is important to know whether drug kinetics change as doses are increased. Doxorubicin was selected because of its broad spectrum of activity and its known efficacy in metastatic breast cancer. Doses of 75, 100, 125 and 150 mg/m2 were given to 11 patients with metastatic breast cancer by infusion over 30 min. Serum concentrations of parent drug and metabolites were determined during the first 48 h following the infusion by high-performance liquid chromatography (HPLC). The serum concentration vs time curve decayed as a triple exponential function in four patients and as a double exponential function in seven. A four-compartment model, one central and three peripheral, would predict concentrations to within 1 SE of the observed values. Doxorubicinol was the principal metabolite, and doxorubicinone and 7-deoxydoxorubicinone were clearly identified. There was a linear increase in the AUC infinity with dose. In addition, a small and transient increase in circulating levels of doxorubicinol and other important metabolites was observed 6 h following the administration of doxorubicin, which suggests the existence of an enterohepatic, or other, re-circulation mechanism. We conclude that in the dose range selected the kinetics of doxorubicin are linear and that the increase in toxicities seen with the higher doses of doxorubicin, following the second and third fortnightly administration, may be due to intracellular drug accumulation in tissues.
CitationComparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. 1990, 25 (6):435-9 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology
- [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
- Authors: Wihlm J, Limacher JM, Levêque D, Duclos B, Dufour P, Bergerat JP, Methlin G
- Issue date: 1997 Jun
- Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
- Authors: Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr, Tkaczuk KH, Boxenbaum H, Welles L, Chow SC, Bhamra R, Chaikin P
- Issue date: 2003 Mar
- Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
- Authors: Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH
- Issue date: 2005 May
- Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
- Authors: Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA
- Issue date: 1991
- Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
- Authors: Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, Fry D, Egorin MJ
- Issue date: 1999 Mar